GLP-1 receptor agonist and use thereof
US11643403B2 · kind B2 · utility
1Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 13, 2020 |
| Grant date | May 9, 2023 |
| Priority date | — |
| Expiry date | Nov 13, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.